Status:
UNKNOWN
Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine
Lead Sponsor:
Hospital Universitário Professor Edgard Santos
Conditions:
Visceral Leishmaniasis
Immune Response
Eligibility:
All Genders
2-50 years
Phase:
NA
Brief Summary
This study is designed to evaluate the immune and therapeutic responses of visceral leishmaniasis patients using N-acetylcysteine (NAC) as an adjuvant therapy to pentavalent antimony.
Detailed Description
In this study we intend to evaluate the immune and therapeutic responses of patients with visceral leishmaniasis N-acetylcysteine (NAC) as an adjuvant to standard treatment with pentavalent antimony, ...
Eligibility Criteria
Inclusion
- Age 2 to 50 years
- Diagnosis of visceral leishmaniasis
Exclusion
- Other acute or chronic diseases
- Use of immunosuppressive drugs
- AIDS
- History of allergy to NAC and/or pentavalent antimony
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01138956
Start Date
April 1 2010
End Date
December 1 2011
Last Update
June 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Aracaju, Sergipe, Brazil, 49060-100